All In Biotech

Drug Trial Radar · NCT07713745

Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jul 18, 2026

Primary completion

Jun 1, 2036

Study completion Dec 31, 2036

Sponsor

Lead sponsor
Beijing Tiantan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an adaptive platform-basket trial that aims to evaluate the safety and efficacy of multiple novel agents and combination therapies in patients with NF2-related schwannomatosis (NF2-SWN). The study employs a basket design to assess treatment responses across four tumor types commonly associated with NF2-SWN: vestibular schwannomas, non-vestibular schwannomas, meningiomas, and ependymomas. A shared natural history observational cohort, receiving routine clinical follow-up without investigational treatment, serves as a common control for all substudies. The adaptive platform enables the dynamic addition or closure of substudies based on interim analyses, thereby optimizing trial efficiency. Eligible patients who meet the master protocol criteria and satisfy substudy-specific safety requirements will be assigned to receive the corresponding intervention. Currently open substudies include: * Substudy A: Selumetinib * Substudy B: Luvometinib plus Serplulimab

Conditions

  • Neurofibromatosis Type 2
  • Vestibular Schwannoma
  • Non-vestibular Schwannoma
  • Meningioma
  • Ependymoma
  • NF2-related Schwannomatosis
  • NF2

Interventions

  • Selumetinib 25mg/m2Drug

    Oral twice daily per predetermined dosage per protocol.

  • LuvometinibDrug

    Oral once daily per predetermined dosage per protocol.

  • SerplulimabDrug

    Intravenous infusion per predetermined dosage per protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tumor-Type-Specific Response Rate in NF2-SWN TumorsTime frame: 12 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Xuanwu Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.